@article {144, title = {A cross-population atlas of genetic associations for 220 human phenotypes.}, journal = {Nat Genet}, volume = {53}, year = {2021}, month = {2021 10}, pages = {1415-1424}, abstract = {

Current genome-wide association studies do not yet capture sufficient diversity in populations and scope of phenotypes. To expand an atlas of genetic associations in non-European populations, we conducted 220 deep-phenotype genome-wide association studies (diseases, biomarkers and medication usage) in BioBank Japan (n = 179,000), by incorporating past medical history and text-mining of electronic medical records. Meta-analyses with the UK Biobank and FinnGen (n = 628,000) identified ~5,000 new loci, which improved the resolution of the genomic map of human traits. This atlas elucidated the landscape of pleiotropy as represented by the major histocompatibility complex locus, where we conducted HLA fine-mapping. Finally, we performed statistical decomposition of matrices of phenome-wide summary statistics, and identified latent genetic components, which pinpointed responsible variants and biological mechanisms underlying current disease classifications across populations. The decomposed components enabled genetically informed subtyping of similar diseases (for example, allergic diseases). Our study suggests a potential avenue for hypothesis-free re-investigation of human diseases through genetics.

}, keywords = {ABO Blood-Group System, Biological Specimen Banks, Genetic Association Studies, Genetic Loci, Genetic Pleiotropy, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Major Histocompatibility Complex, Meta-Analysis as Topic, Mutation, Phenotype}, issn = {1546-1718}, doi = {10.1038/s41588-021-00931-x}, author = {Sakaue, Saori and Kanai, Masahiro and Tanigawa, Yosuke and Karjalainen, Juha and Kurki, Mitja and Koshiba, Seizo and Narita, Akira and Konuma, Takahiro and Yamamoto, Kenichi and Akiyama, Masato and Ishigaki, Kazuyoshi and Suzuki, Akari and Suzuki, Ken and Obara, Wataru and Yamaji, Ken and Takahashi, Kazuhisa and Asai, Satoshi and Takahashi, Yasuo and Suzuki, Takao and Shinozaki, Nobuaki and Yamaguchi, Hiroki and Minami, Shiro and Murayama, Shigeo and Yoshimori, Kozo and Nagayama, Satoshi and Obata, Daisuke and Higashiyama, Masahiko and Masumoto, Akihide and Koretsune, Yukihiro and Ito, Kaoru and Terao, Chikashi and Yamauchi, Toshimasa and Komuro, Issei and Kadowaki, Takashi and Tamiya, Gen and Yamamoto, Masayuki and Nakamura, Yusuke and Kubo, Michiaki and Murakami, Yoshinori and Yamamoto, Kazuhiko and Kamatani, Yoichiro and Palotie, Aarno and Rivas, Manuel A and Daly, Mark J and Matsuda, Koichi and Okada, Yukinori} } @article {82, title = {Electronic health record phenotypes associated with genetically regulated expression of CFTR and application to cystic fibrosis.}, journal = {Genet Med}, volume = {22}, year = {2020}, month = {2020 07}, pages = {1191-1200}, abstract = {

PURPOSE: The increasing use of electronic health records (EHRs) and biobanks offers unique opportunities to study Mendelian diseases. We described a novel approach to summarize clinical manifestations from patient EHRs into phenotypic evidence for cystic fibrosis (CF) with potential to alert unrecognized patients of the disease.

METHODS: We estimated genetically predicted expression (GReX) of cystic fibrosis transmembrane conductance regulator (CFTR) and tested for association with clinical diagnoses in the Vanderbilt University biobank (N = 9142 persons of European descent with 71 cases of CF). The top associated EHR phenotypes were assessed in combination as a phenotype risk score (PheRS) for discriminating CF case status in an additional 2.8 million patients from Vanderbilt University Medical Center (VUMC) and 125,305 adult patients including 25,314 CF cases from MarketScan, an independent external cohort.

RESULTS: GReX of CFTR was associated with EHR phenotypes consistent with CF. PheRS constructed using the EHR phenotypes and weights discovered by the genetic associations improved discriminative power for CF over the initially proposed PheRS in both VUMC and MarketScan.

CONCLUSION: Our study demonstrates the power of EHRs for clinical description of CF and the benefits of using a genetics-informed weighing scheme in construction of a phenotype risk score. This research may find broad applications for phenomic studies of Mendelian disease genes.

}, keywords = {Adult, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Electronic Health Records, Humans, Mutation, Phenotype}, issn = {1530-0366}, doi = {10.1038/s41436-020-0786-5}, author = {Zhong, Xue and Yin, Zhijun and Jia, Gengjie and Zhou, Dan and Wei, Qiang and Faucon, Annika and Evans, Patrick and Gamazon, Eric R and Li, Bingshan and Tao, Ran and Rzhetsky, Andrey and Bastarache, Lisa and Cox, Nancy J} } @article {81, title = {Identification of cancer driver genes based on nucleotide context.}, journal = {Nat Genet}, volume = {52}, year = {2020}, month = {2020 02}, pages = {208-218}, abstract = {

Cancer genomes contain large numbers of somatic mutations but few of these mutations drive tumor development. Current approaches either identify driver genes on the basis of mutational recurrence or approximate the functional consequences of nonsynonymous mutations by using bioinformatic scores. Passenger mutations are enriched in characteristic nucleotide contexts, whereas driver mutations occur in functional positions, which are not necessarily surrounded by a particular nucleotide context. We observed that mutations in contexts that deviate from the characteristic contexts around passenger mutations provide a signal in favor of driver genes. We therefore developed a method that combines this feature with the signals traditionally used for driver-gene identification. We applied our method to whole-exome sequencing data from 11,873 tumor-normal pairs and identified 460 driver genes that clustered into 21 cancer-related pathways. Our study provides a resource of driver genes across 28 tumor types with additional driver genes identified according to mutations in unusual nucleotide contexts.

}, keywords = {Cluster Analysis, Computational Biology, Humans, Mutation, Neoplasms, Nucleotides, Proteins, Whole Exome Sequencing}, issn = {1546-1718}, doi = {10.1038/s41588-019-0572-y}, author = {Dietlein, Felix and Weghorn, Donate and Taylor-Weiner, Amaro and Richters, Andr{\'e} and Reardon, Brendan and Liu, David and Lander, Eric S and Van Allen, Eliezer M and Sunyaev, Shamil R} } @article {63, title = {Identification of rare-disease genes using blood transcriptome sequencing and large control cohorts.}, journal = {Nat Med}, volume = {25}, year = {2019}, month = {2019 06}, pages = {911-919}, abstract = {

It is estimated that 350 million individuals worldwide suffer from rare diseases, which are predominantly caused by mutation in a single gene. The current molecular diagnostic rate is estimated at 50\%, with whole-exome sequencing (WES) among the most successful approaches. For patients in whom WES is uninformative, RNA sequencing (RNA-seq) has shown diagnostic utility in specific tissues and diseases. This includes muscle biopsies from patients with undiagnosed rare muscle disorders, and cultured fibroblasts from patients with mitochondrial disorders. However, for many individuals, biopsies are not performed for clinical care, and tissues are difficult to access. We sought to assess the utility of RNA-seq from blood as a diagnostic tool for rare diseases of different pathophysiologies. We generated whole-blood RNA-seq from 94 individuals with undiagnosed rare diseases spanning 16 diverse disease categories. We developed a robust approach to compare data from these individuals with large sets of RNA-seq data for controls (n = 1,594 unrelated controls and n = 49 family members) and demonstrated the impacts of expression, splicing, gene and variant filtering strategies on disease gene identification. Across our cohort, we observed that RNA-seq yields a 7.5\% diagnostic rate, and an additional 16.7\% with improved candidate gene resolution.

}, keywords = {Acid Ceramidase, Case-Control Studies, Child, Child, Preschool, Cohort Studies, Female, Genetic Variation, Humans, Male, Models, Genetic, Mutation, Oxidoreductases Acting on CH-CH Group Donors, Potassium Channels, Rare Diseases, RNA, RNA Splicing, Sequence Analysis, RNA, Whole Exome Sequencing}, issn = {1546-170X}, doi = {10.1038/s41591-019-0457-8}, author = {Fr{\'e}sard, Laure and Smail, Craig and Ferraro, Nicole M and Teran, Nicole A and Li, Xin and Smith, Kevin S and Bonner, Devon and Kernohan, Kristin D and Marwaha, Shruti and Zappala, Zachary and Balliu, Brunilda and Davis, Joe R and Liu, Boxiang and Prybol, Cameron J and Kohler, Jennefer N and Zastrow, Diane B and Reuter, Chloe M and Fisk, Dianna G and Grove, Megan E and Davidson, Jean M and Hartley, Taila and Joshi, Ruchi and Strober, Benjamin J and Utiramerur, Sowmithri and Lind, Lars and Ingelsson, Erik and Battle, Alexis and Bejerano, Gill and Bernstein, Jonathan A and Ashley, Euan A and Boycott, Kym M and Merker, Jason D and Wheeler, Matthew T and Montgomery, Stephen B} } @article {44, title = {Fine-mapping and functional studies highlight potential causal variants for rheumatoid arthritis and type 1 diabetes.}, journal = {Nat Genet}, volume = {50}, year = {2018}, month = {2018 10}, pages = {1366-1374}, abstract = {

To define potentially causal variants for autoimmune disease, we fine-mapped 76 rheumatoid arthritis (11,475 cases, 15,870 controls) and type 1 diabetes loci (9,334 cases, 11,111 controls). After sequencing 799 1-kilobase regulatory (H3K4me3) regions within these loci in 568 individuals, we observed accurate imputation for 89\% of common variants. We defined credible sets of <=5 causal variants at 5 rheumatoid arthritis and 10 type 1 diabetes loci. We identified potentially causal missense variants at DNASE1L3, PTPN22, SH2B3, and TYK2, and noncoding variants at MEG3, CD28-CTLA4, and IL2RA. We also identified potential candidate causal variants at SIRPG and TNFAIP3. Using functional assays, we confirmed allele-specific protein binding and differential enhancer activity for three variants: the CD28-CTLA4 rs117701653 SNP, MEG3 rs34552516 indel, and TNFAIP3 rs35926684 indel.

}, keywords = {Alleles, Arthritis, Rheumatoid, Case-Control Studies, CD28 Antigens, Chromosome Mapping, CTLA-4 Antigen, Diabetes Mellitus, Type 1, Gene Frequency, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Jurkat Cells, Mutation, Polymorphism, Single Nucleotide, Quantitative Trait Loci, RNA, Long Noncoding, Tumor Necrosis Factor alpha-Induced Protein 3}, issn = {1546-1718}, doi = {10.1038/s41588-018-0216-7}, author = {Westra, Harm-Jan and Mart{\'\i}nez-Bonet, Marta and Onengut-Gumuscu, Suna and Lee, Annette and Luo, Yang and Teslovich, Nikola and Worthington, Jane and Martin, Javier and Huizinga, Tom and Klareskog, Lars and Rantapaa-Dahlqvist, Solbritt and Chen, Wei-Min and Quinlan, Aaron and Todd, John A and Eyre, Steve and Nigrovic, Peter A and Gregersen, Peter K and Rich, Stephen S and Raychaudhuri, Soumya} } @article {11, title = {Estimating the selective effects of heterozygous protein-truncating variants from human exome data.}, journal = {Nat Genet}, volume = {49}, year = {2017}, month = {2017 May}, pages = {806-810}, abstract = {

The evolutionary cost of gene loss is a central question in genetics and has been investigated in model organisms and human cell lines. In humans, tolerance of the loss of one or both functional copies of a gene is related to the gene{\textquoteright}s causal role in disease. However, estimates of the selection and dominance coefficients in humans have been elusive. Here we analyze exome sequence data from 60,706 individuals to make genome-wide estimates of selection against heterozygous loss of gene function. Using this distribution of selection coefficients for heterozygous protein-truncating variants (PTVs), we provide corresponding Bayesian estimates for individual genes. We find that genes under the strongest selection are enriched in embryonic lethal mouse knockouts, Mendelian disease-associated genes, and regulators of transcription. Screening by essentiality, we find a large set of genes under strong selection that are likely to have crucial functions but have not yet been thoroughly characterized.

}, keywords = {Algorithms, Animals, Bayes Theorem, Exome, Gene Frequency, Genetic Predisposition to Disease, Genetic Variation, Genome-Wide Association Study, Genotype, Heterozygote, Humans, Mice, Knockout, Models, Genetic, Mutation, Selection, Genetic, Sequence Analysis, DNA}, issn = {1546-1718}, doi = {10.1038/ng.3831}, author = {Cassa, Christopher A and Weghorn, Donate and Balick, Daniel J and Jordan, Daniel M and Nusinow, David and Samocha, Kaitlin E and O{\textquoteright}Donnell-Luria, Anne and MacArthur, Daniel G and Daly, Mark J and Beier, David R and Sunyaev, Shamil R} } @article {33, title = {Whole-transcriptome sequencing in blood provides a diagnosis of spinal muscular atrophy with progressive myoclonic epilepsy.}, journal = {Hum Mutat}, volume = {38}, year = {2017}, month = {2017 06}, pages = {611-614}, abstract = {

At least 15\% of the disease-causing mutations affect mRNA splicing. Many splicing mutations are missed in a clinical setting due to limitations of in silico prediction algorithms or their location in noncoding regions. Whole-transcriptome sequencing is a promising new tool to identify these mutations; however, it will be a challenge to obtain disease-relevant tissue for RNA. Here, we describe an individual with a sporadic atypical spinal muscular atrophy, in whom clinical DNA sequencing reported one pathogenic ASAH1 mutation (c.458A>G;p.Tyr153Cys). Transcriptome sequencing on patient leukocytes identified a highly significant and atypical ASAH1 isoform not explained by c.458A>G(p<10 ). Subsequent Sanger-sequencing identified the splice mutation responsible for the isoform (c.504A>C;p.Lys168Asn) and provided a molecular diagnosis of autosomal-recessive spinal muscular atrophy with progressive myoclonic epilepsy. Our findings demonstrate the utility of RNA sequencing from blood to identify splice-impacting disease mutations for nonhematological conditions, providing a diagnosis for these otherwise unsolved patients.

}, keywords = {Acid Ceramidase, Child, Preschool, Humans, Male, Muscular Atrophy, Spinal, Mutation, Myoclonic Epilepsies, Progressive, Pathology, Molecular, RNA Splicing, Sequence Analysis, DNA, Transcriptome}, issn = {1098-1004}, doi = {10.1002/humu.23211}, author = {Kernohan, Kristin D and Fr{\'e}sard, Laure and Zappala, Zachary and Hartley, Taila and Smith, Kevin S and Wagner, Justin and Xu, Hongbin and McBride, Arran and Bourque, Pierre R and Consortium, Care Rare Canada and Bennett, Steffany A L and Dyment, David A and Boycott, Kym M and Montgomery, Stephen B and Warman Chardon, Jodi} }